Somaxon Pharmaceuticals Inc

Premium Company Profile

Publication Date	March 2008
Publisher	Datamonitor
Product Type	Databook
Pages	41
ISBN Number	not applicable
Product Code	DAT10940

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

Somaxon Pharmaceuticals (Somaxon) is a development stage pharmaceutical company engaged in in-licensing and developing proprietary product candidates for the treatment of psychiatry and neurology disorders. In January 2008, Somaxon submitted NDA with the FDA for Silenor for the treatment of insomnia.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Somaxon Pharmaceuticals enters into licensing agreements with pharmaceutical companies for developing therapeutics. In 2003, the company entered into licensing agreement with ProCom One for the exclusive, worldwide license to certain patents to develop and commercialize low dosages of Silenor for the treatment of insomnia. In the following year, BioTie Therapies granted the license of oral nalmefene hydrochloride to Somaxon. In addition, Somaxon received exclusive worldwide rights from Synchroneuron to certain patents to develop, manufacture and market acamprosate. During the forecast period 2006-2010, Somaxon is expected to derive its entire revenues from the launch of Silenor in 2009. Product sales of Silenor are expected to grow from $71 million in 2009 to $119 million in 2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.

Content

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
Ac Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Somaxon Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 1: Somaxon Pharmaceuticals - Key Facts
- Table 2: Somaxon Pharmaceuticals - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Somaxon Pharmaceuticals - Key Events Impacting Share Price Performance
- Table 4: Somaxon Pharmaceuticals - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: Somaxon Pharmaceuticals - Balance Sheet
- Table 6: Somaxon Pharmaceuticals - Cash Flow
- Table 7: Somaxon Pharmaceuticals - in-house Pipeline Products
- Table 8: Somaxon Pharmaceuticals - Forecast Sales, 2006-2010 ($ Mn)
- Table 9: Somaxon Pharmaceuticals - Key Competitors
- Table 10: Somaxon Pharmaceuticals - Key Suppliers
- Table 11: Somaxon Pharmaceuticals - Key Shareholders
- Table 12: Somaxon Pharmaceuticals - SWOT Analysis Summary
- Table 13: Somaxon Pharmaceuticals - Value Chain Analysis
- Table 14: Somaxon Pharmaceuticals - Key Employees
- Table 15: Somaxon Pharmaceuticals- Financial and Operational Overview